CLINICAL_TRIALS
trial_result
· 2017-02-20
Clinical Trial Update: Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment [Phase 1]
Summary
Phase 1 trial evaluating the pharmacokinetics and safety of regorafenib in cancer patients with severe renal impairment; results were posted on 2017-02-20.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2017-02-20